Quantifying Biomarkers in the Eye for Better Clinical Outcomes
Zilia combines imaging, spectrometry and AI for the detection of biomarkers involved in ocular, neurological and systemic conditions.
What if we could prevent vision loss?
Failure to detect ocular diseases early-on has a significant impact on the health of patients, treatment outcomes, health care costs and quality of life.
Early detection is key, but to enable it, eye-care professionals must be equipped with the proper tools. As oxygen regulation is linked to major ocular diseases, oxygen saturation can be tracked and measured as an early biomarker, helping prevent their progression.
Ratio of undiagnosed diseases in industrialized countries
That’s where our solution
comes into play
The idea
Using light to provide crucial information on the health of ocular tissues and the processes involved in ocular diseases.
The technology
Quantitative, non invasive, continuous, real-time, full light spectrum analysis for ocular oximetry.
The potential
Revolutionize the way we prevent, screen, diagnose and treat patients with ocular diseases.
Developing Innovative
non-invasive oximetry technologies revolutionizing eye care
Our technology uses the power of light to provide scientists and eye-care professionals with vital information on the metabolic state of the eye to better manage ocular diseases.
What experts say about Zilia
Zilia’s ocular oximetry technology can capture real-time metabolic information of the retina and optic nerve, which has the potential to transform diagnosis and management of retinal diseases.
The technology behind Zilia is poised to open a new way in management of ocular diseases. The ability to measure oxygen levels non-invasively will provide ophthalmologists with a better understanding of the disease process, thus helping patients achieve better visual outcomes in some of these serious and potentially blinding ocular diseases.
Zilia’s ocular oximetry technology will not only be a valuable tool for eye and vision research but will certainly become an essential means for the early detection of ocular and systemic diseases in clinical settings.
Our Partners
With the help of
TECHNOLOGY
475 Grande-Allée Est
Québec, Québec
G1R 2J5, CANADA
1.833.501.6996
REGULATORY